Resources

In part 9, the conclusion of this Exclusive Interview, Dr. Carla Greenbaum talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California about the realities of where diabetes research can be in the next five or more years, in relation to a cure as well as other types of treatments.

So many of my patients who have insulin resistance, type 1 or type 2 diabetes with hyperglycemia and/or obesity have vitamin D or vitamin B12 deficiency. Often they have never had their levels checked or, if they have, were diagnosed with either or both vitamin D deficiency and vitamin B12 deficiency and do not take their prescribed vitamins. Why?

In part 5 of this Exclusive Interview, Dr. Aaron Vinik talks with Diabetes in Control Publisher Steve Freed during the AACE 2017 convention in Austin, Texas about the need to continue research into drugs such as SGLT-2s because breakthroughs may possibly be found in these medications.

In this week's Homerun Slides, medication trial results, long-acting insulins, and treating prediabetes.

Hypertriglyceridemia and low HDL cholesterol, increased risk of type 2 diabetes: Under fasting conditions, the liver of subjects with NAFLD overproduces triglyceride-enriched VLDL particles despite hyperinsulinemia when compared to equally obese subjects without NAFLD. Insulin normally decreases production of VLDL by inhibiting adipose tissue lipolysis, and by directly suppressing hepatic production of VLDL.

Coronary artery calcium (CAC) scores better at predicting risk of cardiovascular disease (CVD) event in patients with type 2 than traditional scores.

UK-based study compares drug classes over 4-year period.

Study compares effectiveness of oral GLP-1 medication over injection.

Determining which patients benefit most from lifestyle, metformin interventions may improve individualized care decisions.

By Sheri R. Colberg, PhD: Much of the research on length of life for individuals living with type 1 diabetes is pessimistic, which makes a new study released recently a breath of fresh air. Data were collected for the ongoing nationwide, multicenter, Finnish Diabetic Nephropathy (FinnDiane) Study that tracked the death rate of 2,639 study participants.